Compare BWAY & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWAY | MRVI |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 450.8M | 472.8M |
| IPO Year | N/A | 2020 |
| Metric | BWAY | MRVI |
|---|---|---|
| Price | $13.77 | $3.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $13.25 | $4.57 |
| AVG Volume (30 Days) | 91.8K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $185,743,000.00 |
| Revenue This Year | $314.08 | $11.80 |
| Revenue Next Year | $23.37 | $7.74 |
| P/E Ratio | $81.98 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.84 | $1.67 |
| 52 Week High | $26.63 | $4.11 |
| Indicator | BWAY | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 30.17 | 53.21 |
| Support Level | $11.55 | $3.25 |
| Resistance Level | $17.20 | $3.65 |
| Average True Range (ATR) | 1.13 | 0.18 |
| MACD | -1.20 | 0.03 |
| Stochastic Oscillator | 16.10 | 56.11 |
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.